ABAX Insider Trading
ABAX | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at ABAX provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2012-02-10 03:25 | 2012-02-07 | EVENHUIS HENK | Director | OPT+S | $28.91 | 5,000 | $144,565 | 8,900 | 0.0% |
| 2011-12-08 20:07 | 2011-12-07 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $28.02 | 5,133 | $143,837 | 0 | -100.0% |
| 2011-12-07 22:07 | 2011-12-05 | SEVERSON CLINTON | Director, Officer - President,CEO & Board Chairman | OPT+S | $28.41 | 9,000 | $255,689 | 508,852 | 0.0% |
| 2011-12-07 20:33 | 2011-12-06 | INES ALBERTO SANTA | Officer - CFO and VP of Finance | SELL | $28.36 | 5,000 | $141,782 | 67,569 | -6.9% |
| 2011-12-05 21:35 | 2011-12-01 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $27.84 | 2,900 | $80,736 | 5,133 | -36.1% |
| 2011-12-01 20:34 | 2011-11-30 | INES ALBERTO SANTA | Officer - CFO and VP of Finance | SELL | $25.88 | 15,000 | $388,200 | 72,569 | -17.1% |
| 2011-11-17 19:39 | 2011-11-15 | Henkel Achim | Officer - Managing Director-Europe | SELL | $27.50 | 5,000 | $137,500 | 14,750 | -25.3% |
| 2011-10-29 01:06 | 2011-10-28 | OSTOICH VLADIMIR | Officer - VP of Govt Affairs & Pac Rim | SELL | $29.01 | 10,000 | $290,082 | 382,313 | -2.5% |
| 2011-10-27 01:44 | 2011-10-26 | Mulroy Martin | Officer - VP-Sales & Mktg, Animal Health | SELL | $28.67 | 2,374 | $68,055 | 24,765 | -8.7% |
| 2011-06-23 23:52 | 2011-05-27 | BASTIANI RICHARD | Director | SELL | $30.45 | 12,000 | $365,449 | 42,900 | -21.9% |
| 2011-06-07 22:23 | 2011-06-06 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $28.27 | 4,000 | $113,084 | 6,033 | -39.9% |
| 2011-06-02 19:04 | 2011-06-01 | ARON KENNETH | Officer - Chief Technology Officer | SELL | $30.22 | 10,000 | $302,172 | 39,170 | -20.3% |
| 2011-05-24 00:34 | 2011-05-19 | Henkel Achim | Officer - Managing Director-Europe | SELL | $28.65 | 2,000 | $57,300 | 19,750 | -9.2% |
| 2011-05-20 19:28 | 2011-05-19 | Mulroy Martin | Officer - VP-Sales & Mktg, Animal Health | SELL | $30.80 | 3,826 | $117,841 | 27,130 | -12.4% |
| 2011-05-06 23:22 | 2011-05-05 | TUCKER ERNEST | Director | SELL | $27.91 | 2,200 | $61,412 | 0 | -100.0% |
| 2011-04-09 04:16 | 2011-04-07 | Mulroy Martin | Officer - VP-Sales & Mktg, Animal Health | SELL | $30.24 | 2,699 | $81,618 | 17,846 | -13.1% |
| 2011-03-09 02:28 | 2011-03-07 | Mulroy Martin | Officer - VP-Sales & Mktg, Animal Health | SELL | $27.52 | 3,649 | $100,414 | 20,545 | -15.1% |
| 2011-03-09 01:49 | 2011-03-08 | WOOD DONALD PETER | Officer - Chief Operations Officer | SELL | $27.02 | 6,460 | $174,549 | 0 | -100.0% |
| 2011-03-04 22:15 | 2011-03-02 | EVENHUIS HENK | Director | OPT+S | $27.12 | 5,000 | $135,584 | 6,700 | 0.0% |
| 2011-03-02 20:33 | 2011-03-01 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $26.25 | 4,500 | $118,143 | 36,051 | 0.0% |
| 2011-02-18 19:35 | 2011-02-11 | Henkel Achim | Officer - Managing Director-Europe | SELL | $26.50 | 3,000 | $79,500 | 15,250 | -16.4% |
| 2011-02-18 03:09 | 2011-02-16 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $27.24 | 1,000 | $27,241 | 9,400 | -9.6% |
| 2011-02-11 00:10 | 2011-02-08 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $26.37 | 3,000 | $79,123 | 10,400 | -22.4% |
| 2010-12-14 22:37 | 2010-12-08 | OSTOICH VLADIMIR | Officer - VP of Govt Affairs & Pac Rim | SELL | $28.33 | 12,000 | $340,019 | 326,601 | -3.5% |
| 2010-12-14 20:36 | 2010-11-26 | Henkel Achim | Officer - Managing Director-Europe | SELL | $26.67 | 3,000 | $80,010 | 18,250 | -14.1% |
| 2010-12-11 03:31 | 2010-12-08 | SEVERSON CLINTON | Director, Officer - President,CEO & Board Chairman | SELL | $28.23 | 35,000 | $987,980 | 494,220 | -6.6% |
| 2010-12-09 03:34 | 2010-12-03 | SEVERSON CLINTON | Director, Officer - President,CEO & Board Chairman | OPT+S | $28.10 | 96,000 | $2,697,600 | 529,220 | 0.0% |
| 2010-12-08 04:44 | 2010-12-03 | SEVERSON CLINTON | Director, Officer - President,CEO & Board Chairman | OPT+S | $27.99 | 66,029 | $1,848,284 | 475,220 | 0.0% |
| 2010-12-03 21:03 | 2010-12-01 | BASTIANI RICHARD | Director | SELL | $27.80 | 9,000 | $250,200 | 52,700 | -14.6% |
| 2010-11-12 19:20 | 2010-11-10 | BASTIANI RICHARD | Director | SELL | $26.30 | 6,000 | $157,800 | 61,700 | -8.9% |
| 2010-09-08 21:54 | 2010-09-07 | Henkel Achim | Officer - Managing Director-Europe | SELL | $19.50 | 4,347 | $84,767 | 13,250 | -24.7% |
| 2010-09-04 01:55 | 2010-09-03 | Henkel Achim | Officer - Managing Director-Europe | SELL | $19.50 | 653 | $12,734 | 17,597 | -3.6% |
| 2010-08-19 00:25 | 2010-08-17 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $19.84 | 5,000 | $99,202 | 12,400 | -28.7% |
| 2010-05-28 22:10 | 2010-05-27 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $22.73 | 8,250 | $187,523 | 26,020 | 0.0% |
| 2010-05-27 21:59 | 2010-05-25 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $22.08 | 13,000 | $287,034 | 26,020 | 0.0% |
| 2010-05-13 21:59 | 2010-05-11 | TUCKER ERNEST | Director | SELL | $24.55 | 2,200 | $54,012 | 0 | -100.0% |
| 2010-05-13 21:41 | 2010-05-12 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $25.16 | 3,125 | $78,624 | 26,020 | 0.0% |
| 2010-04-28 20:43 | 2010-04-26 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $27.09 | 3,125 | $84,663 | 13,198 | 0.0% |
| 2010-04-07 00:58 | 2010-04-05 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $27.06 | 3,125 | $84,549 | 13,198 | 0.0% |
| 2010-03-24 01:21 | 2010-03-22 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $27.84 | 3,125 | $87,013 | 13,198 | 0.0% |
| 2010-03-17 00:32 | 2010-03-15 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $27.28 | 3,125 | $85,238 | 13,198 | 0.0% |
| 2010-03-10 01:21 | 2010-03-05 | OSTOICH VLADIMIR | Officer - VP of Govt Affairs & Pac Rim | SELL | $26.00 | 16,000 | $416,000 | 317,500 | -4.8% |
| 2010-03-03 03:12 | 2010-03-01 | ARON KENNETH | Officer - Chief Technology Officer | OPT+S | $25.86 | 3,125 | $80,824 | 13,198 | 0.0% |
| 2010-03-03 02:36 | 2010-03-01 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $25.89 | 2,000 | $51,780 | 17,400 | -10.3% |
| 2010-03-02 21:19 | 2010-02-11 | Henkel Achim | Officer - Managing Director-Europe | SELL | $24.51 | 5,000 | $122,550 | 12,750 | -28.2% |
| 2010-02-11 22:31 | 2010-02-10 | TUCKER ERNEST | Director | SELL | $23.15 | 5,000 | $115,750 | 0 | -100.0% |
| 2010-01-20 18:36 | 2009-12-08 | Henkel Achim | Officer - Managing Director-Europe | OPT+S | $23.75 | 2,000 | $47,500 | 12,750 | 0.0% |
| 2009-11-07 02:03 | 2009-11-03 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | OPT+S | $22.88 | 2,000 | $45,750 | 3,400 | 0.0% |
| 2009-10-30 21:58 | 2009-10-29 | HANLON BRENTON | Officer - VP-Sales & Marketing,Medical | SELL | $23.60 | 1,000 | $23,600 | 5,400 | -15.6% |
| 2009-09-05 02:34 | 2009-09-04 | HANLON BRENTON | Officer - VP-Sales&Marketing,Medical | SELL | $26.63 | 1,000 | $26,630 | 6,400 | -13.5% |
How to Interpret $ABAX Trades
Not every insider transaction in ABAX is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ABAX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for ABAX
Insider activity data for ABAX is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ABAX, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.